The system that determines who can access life-saving medicines reflects the power of the institutions that control that access, not the medical need of the people who lack it.
How Access Is Determined
Access to pharmaceutical medicines is determined not primarily by medical need but by the intersection of three institutional power structures: the patent system that grants pharmaceutical companies exclusive market rights; the regulatory system that determines which medicines may be sold in which markets; and the financing system that determines whether the people who need medicines have the resources to purchase them at the prices the patent system enables. This intersection produces a specific access architecture: comprehensive access for people in high-income countries with robust pharmaceutical financing, partial access for middle-income countries, and severely constrained access for low-income countries where pharmaceutical prices exceed what the financing system and most individuals can afford.
The Generic Medicines Tension
The generic medicines system — production of medicines whose patent protection has expired by manufacturers who can produce them at marginal cost — is the primary mechanism through which pharmaceutical access is eventually extended to low-income populations. The tension between the generic medicines system and the patent-based pharmaceutical innovation system is structural: the patent protection that makes pharmaceutical innovation financially viable also delays the generic access that would extend the benefits of that innovation to the populations who need it most.
Pharmaceutical access is a governance question dressed in medical language. The question of who gets which medicines at which prices is answered by institutions with specific power interests — not by medical need, which is abundant and unequal, and not by production capacity, which is sufficient. The answer reveals whose interests those institutions are designed to serve.
Discussion